Analyst consensus rating
Ovid Therapeutics Analyst Rating: Strong Buy
Direct answer
Ovid Therapeutics's consensus rating is Strong Buy.
10 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $6.15.
Forecast evidence checked November 21, 2026.
Get free Ovid Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $2.20
- Average price target
- $6.15
- High price target
- $9.00
- Low price target
- $4.00
- Low target gap
- +81.8%
- Target upside
- +179.5%
- High target gap
- +309.1%
- Target range width
- 227.3%
- Consensus rating
- Strong Buy
- Analysts
- 10
- Evidence date
- November 21, 2026
- Valid through
- November 28, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Ovid Therapeutics?
Ovid Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $6.15.
How far are Ovid Therapeutics's low and high targets from the recorded price?
The low target implies +81.8%, while the high target implies +309.1%.
How many analysts are included in Ovid Therapeutics's consensus?
The verified consensus includes 10 analysts.
How is Ovid Therapeutics's target upside or downside calculated?
The average target of $6.15 is divided by the recorded price of $2.20, then one is subtracted to produce +179.5%. This does not guarantee a future return.
When was Ovid Therapeutics's analyst forecast verified?
The data was verified on 2026-11-21. The dataset is valid through 2026-11-28.